Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents

Taotao Yan,Jiuping Wang,Juan Li,Shan Fu,Yi Chen,Chunhua Hu,Rou Zhang,Zhen Tian,Fahui Zhao,Jun Dong,Jinfeng Liu,Yuan Yang,Tianyan Chen,Yingren Zhao,Yingli He

Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents

2019

Taotao Yan
Jiuping Wang
Juan Li
Shan Fu
Yi Chen
Chunhua Hu
Rou Zhang
Zhen Tian
Fahui Zhao
Jun Dong
Jinfeng Liu
Yuan Yang
Tianyan Chen
Yingren Zhao
Yingli He

Background Sofosbuvir is the keystone of direct antiviral agents for the chronic hepatitis C (CHC). The safety of sofosbuvir in patients with stage 4–5 chronic kidney disease (CKD) needs further observation in real world.

Keywords:

Hyperkalemia
Medicine
Virology
Sofosbuvir
Medical microbiology
Tropical medicine
Kidney disease
Hepatitis C
Parasitology
Internal medicine
Hepatitis C virus
Renal function
Gastroenterology
Hemodialysis
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations